Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04812145

Enrollment

Registered

2021-03-23

Start date

2021-04-01

Completion date

2023-04-01

Last updated

2021-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder Cancer

Brief summary

Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.

Interventions

RADIATIONChemoradiation

Hypofractionated radiotherapy with concurrent Gemcitabine

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- Pathologically confirmation of transitional cell carcinoma . Non metastatic invasive bladder cancer (TNM0) Any age group ≥ 18 years. Non pregnant female patients.

Exclusion criteria

\- Other pathology than Transitional cell carcinoma Metastatic Patient Age less than 18 years

Design outcomes

Primary

Measure	Time frame	Description
Response to hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer	baseline	Estimate Disease free survival .

Contacts

Primary ContactEsraa Mostafa Abdelzahir, Master degree

Essra.mostafa1993@gmail.com+201093534631

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026